Pancreatic, thyroid, and other endocrine cancers:
Indications for: ZANOSAR
Symptomatic or progressive metastatic pancreatic islet cell cancer.
Adult Dosage:
1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity.
Children Dosage:
Not recommended.
Boxed Warning:
Should be administered under the supervision of an experienced physician. Have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and toxicity. Mutagenic, tumorigenic, or carcinogenic.
ZANOSAR Warnings/Precautions:
Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see full labeling). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
ZANOSAR Classification:
Nitrosurea.
ZANOSAR Interactions:
Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity.
Adverse Reactions:
GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression).
How Supplied:
Single-use vial—1
